Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients? - Wikidata - awgldk - TriplyDB

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

http://www.wikidata.org/entity/Q47607468

about

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

http://www.wikidata.org/entity/Q47607468

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

@en

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

@nl

type

label

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

@en

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

@nl

prefLabel

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

@en

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

@nl

P1433

Q47607468-CC7F132C-3D88-4940-B2E4-57E5829C4BF0

P1476

Q47607468-831520FB-73DF-4560-A2DC-CDA63F61D01D

P2093

Q47607468-37A9518E-FD6D-4E6A-937E-199A76113AAF

Q47607468-B48721F1-FC84-446F-AA45-A26AB305E716

P2860

Q47607468-0FF9330D-D84C-43E2-B0F8-862CBBA86687

Q47607468-1BA008A8-43A7-4CE0-9125-4235E7ACECD3

Q47607468-2A98DB17-4722-4E4E-A5EF-3906696CFC0D

Q47607468-2E4FFA86-766B-4055-8FD4-2B0F3BEC1186

Q47607468-2FE931C2-870F-49BC-9CEC-09DED71AD8AE

Q47607468-37BB6E82-7AE7-413E-8F0B-5996E12E2B5B

Q47607468-3B4E4681-D6CD-4A07-90F4-4553F3B30DB0

Q47607468-4BCEFB15-0976-40FC-8F18-281A796BBC48

Q47607468-5FB3556C-CD2D-4F1A-ABA5-3668420E37D5

Q47607468-6148B745-35FE-4E3E-B0FF-E5918E071465

P31

Q47607468-FFB34E54-BFC0-4B0B-A2D3-E2144CF4CF82

P356

Q47607468-BDED66AD-0611-4F30-8F89-59C70B787B70

P50

Q47607468-96A0DDD0-6C98-48A6-B2AA-BD89D4BF8CE6

P577

Q47607468-DC264005-0321-4108-AB8C-1C380C4DFEBE

P698

Q47607468-7BED3229-2FD8-45F0-B513-B560B1F80789

P356

S10067-017-3867-3

P1433

Clinical Rheumatology

P1476

Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?

@en

P2093

Ana Catarina Duarte

http://www.w3.org/2001/XMLSchema#string

Ana Cordeiro

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

Pirfenidone in idiopathic pulmonary fibrosis

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

B cells in systemic sclerosis: a possible target for therapy.

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Cyclophosphamide versus placebo in scleroderma lung disease.

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis.

P31

scholarly article

P356

10.1007/S10067-017-3867-3

http://www.w3.org/2001/XMLSchema#string

P50

Maria J. Santos

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29038968

http://www.w3.org/2001/XMLSchema#string